What is SNDX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.52B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SNDX?

P/E (TTM) is n/a and 52-week range is $12.99 to $25.59 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SNDX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SNDX?

The company profile lists revenue (TTM) near $251M, net income (TTM) near $-21.98B, EPS (TTM) near $-2.52 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Syndax Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 88.6M shares outstanding, ISIN US87164F1057 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Syndax Pharmaceuticals Inc

$SNDX

Health Care · Biotechnology

IR Run Scenarios

$16.99

+0.53%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. The company is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. The company is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Employees

298

Website

syndax.com/

IPO

2016-03-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)